Neonatal Hyperbilirubinemia: Total vs. Direct, the Bhutani Nomogram, and When Jaundice Is Never “Just Physiologic”

Direct bilirubin >1.0 mg/dL is always pathologic. Always. No exceptions.

Nearly every newborn develops some degree of jaundice. The vast majority is physiologic—a normal consequence of increased bilirubin production from fetal RBC turnover plus immature hepatic conjugation. But buried in that sea of yellow babies are the ones with pathologic hyperbilirubinemia who need urgent phototherapy or exchange transfusion to prevent kernicterus. The labs tell you which is which.

Total Bilirubin vs. Direct Bilirubin: Why Both Matter

Type	Also Called	What It Means	Clinical Significance
Indirect (Unconjugated)	Lipid-soluble bilirubin	Bilirubin that has NOT been processed by the liver	This is the neurotoxic fraction. Crosses the blood-brain barrier. Elevated in hemolysis, physiologic jaundice, breastfeeding/breast milk jaundice, G6PD deficiency.
Direct (Conjugated)	Water-soluble bilirubin	Bilirubin conjugated by the liver but not excreted into bile	Elevated = cholestasis. Always pathologic in a neonate. Think biliary atresia, neonatal hepatitis, choledochal cyst, metabolic disease, infection.

The Rule That Saves Lives

Direct bilirubin >1.0 mg/dL (or >20% of total bilirubin) is ALWAYS pathologic in a neonate. It is never physiologic. It requires immediate workup for cholestatic causes—most urgently biliary atresia, which has a narrow surgical window (Kasai portoenterostomy must be performed before 60 days of life for best outcomes). A jaundiced baby with pale/acholic stools and dark urine needs urgent referral to pediatric GI/surgery.

The Bhutani Nomogram and Risk Stratification

The Bhutani nomogram (2004, updated in the 2022 AAP guidelines) plots total serum bilirubin (TSB) or transcutaneous bilirubin (TcB) against age in hours to assign risk zone:

Risk Zone	Interpretation	Action
High-risk (>95th percentile)	TSB rising rapidly; high likelihood of needing phototherapy	Start phototherapy per hour-specific thresholds. Evaluate for hemolysis (DAT, reticulocyte count, smear).
High-intermediate (75th–95th)	Significant risk of crossing phototherapy threshold	Close follow-up (recheck TSB in 6–12 hours). Evaluate risk factors.
Low-intermediate (40th–75th)	Moderate risk	Routine follow-up. Recheck at next well visit or sooner if risk factors present.
Low-risk (<40th percentile)	Low likelihood of significant hyperbilirubinemia	Routine care.

2022 AAP Updates

The 2022 AAP clinical practice guideline replaced the 2004 version with key changes: separate phototherapy threshold graphs based on gestational age and neurotoxicity risk factors (isoimmune hemolytic disease, G6PD deficiency, albumin <3.0), universal predischarge bilirubin screening (TSB or TcB) for all newborns, and escalation pathways including when to consider exchange transfusion. The hour-specific approach remains: the same TSB value means different things at 24 hours of age vs. 72 hours of age.

The Workup When Bilirubin Is Concerning

Step 1: Is It Hemolysis?

• Direct Antiglobulin Test (DAT / Coombs): Positive = immune-mediated hemolysis (ABO incompatibility, Rh disease). This is the most common pathologic cause of severe neonatal jaundice.
• Reticulocyte count: Elevated = increased RBC production to compensate for destruction
• Peripheral smear: Spherocytes (hereditary spherocytosis or ABO incompatibility), schistocytes (rare causes)
• G6PD level: Check in at-risk populations (African, Mediterranean, Asian descent) or when hemolysis is present without positive DAT. G6PD deficiency is the most common enzyme deficiency worldwide and an underdiagnosed cause of severe neonatal jaundice.
• Blood type (mother and baby): ABO and Rh typing. O mother + A or B baby = ABO incompatibility risk. Rh-negative mother + Rh-positive baby = Rh disease risk (should have been prevented with RhoGAM).

Step 2: Is There Cholestasis?

• Fractionated bilirubin: If direct >1.0 mg/dL or >20% of total
• GGT, alkaline phosphatase (cholestasis markers)
• Stool color: Acholic (pale/clay) stools = biliary atresia until proven otherwise
• Liver ultrasound: Triangular cord sign, absent/abnormal gallbladder (biliary atresia), choledochal cyst
• HIDA scan if ultrasound inconclusive
• Metabolic workup: Galactosemia (reducing substances in urine), alpha-1 antitrypsin level, thyroid function, urine organic acids

Physiologic vs. Pathologic: The Clinical Distinction

Feature	Physiologic	Pathologic
Onset	After 24 hours of life	Within first 24 hours (always pathologic)
TSB rise	<5 mg/dL/day	>5 mg/dL/day or >0.2 mg/dL/hour
Peak TSB	<12–15 mg/dL (term)	>age-specific phototherapy threshold
Duration	Resolves by 1–2 weeks (term), 2–3 weeks (preterm)	Persists beyond 2 weeks
Direct bilirubin	<1.0 mg/dL	>1.0 mg/dL (always pathologic)

Pediatric Pearl

Jaundice within the first 24 hours of life is NEVER physiologic. It requires immediate evaluation for hemolytic disease (DAT, CBC, reticulocyte count, blood type). Don't wait for the TSB to rise further.

Breastfeeding Jaundice vs. Breast Milk Jaundice

These are two different entities that cause confusion:

• Breastfeeding jaundice (days 2–5): Due to inadequate milk intake and dehydration, leading to decreased bilirubin elimination. Fix: increase feeding frequency, lactation support, supplement if needed. This is a starvation problem, not a breast milk problem.
• Breast milk jaundice (after day 5, peaking at 2 weeks): Due to substances in breast milk that inhibit hepatic conjugation. Benign. TSB rarely exceeds 20. Can persist for 3–12 weeks. Diagnosis of exclusion—rule out other causes first. Do NOT stop breastfeeding.

The Pitfalls

• Visual assessment is unreliable: Dark-skinned infants can have significant hyperbilirubinemia without visible jaundice. Always measure with TcB or TSB.
• Early discharge risk: Babies discharged at 24–48 hours haven't yet reached peak bilirubin. The AAP mandates a follow-up visit within 1–2 days of discharge for bilirubin reassessment.
• G6PD is missed: It's not on every state's newborn screen. A DAT-negative infant with severe hemolytic jaundice should have G6PD checked. Triggers include maternal ingestion of fava beans (if breastfeeding), naphthalene exposure, and certain medications.
• TcB is a screening tool: If TcB is above or near the phototherapy threshold, confirm with serum TSB before making treatment decisions.
• Don't forget the direct bilirubin: In the rush to manage total bilirubin and phototherapy, the direct fraction can be overlooked. Every jaundiced baby beyond 2–3 weeks needs a fractionated bilirubin. Biliary atresia has a surgical deadline.

Bottom Line

Neonatal jaundice is common; pathologic jaundice is the emergency hiding inside. Jaundice at <24 hours = always pathologic. Direct bilirubin >1.0 = always pathologic. Use the Bhutani nomogram with hour-specific thresholds. Check a DAT and G6PD when hemolysis is suspected. And never let a cholestatic baby slip through without an urgent referral—biliary atresia doesn't wait.

Stay sharp out there.

ASO Titers & Anti-DNase B: When They Matter, When They Don't, and the Jones Criteria Refresher

 

ASO Titers & Anti-DNase B: When They Matter, When They Don't, and the Jones Criteria Refresher

Stop ordering ASO for every sore throat. It's only relevant when you suspect a post-streptococcal complication—not for diagnosing acute pharyngitis.

What ASO and Anti-DNase B Measure

Both are antibodies against Group A Streptococcus (GAS) antigens. They indicate prior streptococcal infection—not current infection. They peak 3–6 weeks after the strep infection and decline over months.

• ASO (Anti-Streptolysin O): Rises after pharyngeal GAS infection. Peaks at 3–5 weeks. More sensitive for post-pharyngitis complications (ARF, PSGN).
• Anti-DNase B: Rises after both pharyngeal AND skin GAS infections. Peaks at 6–8 weeks. More sensitive for post-skin-infection complications (especially PSGN after impetigo). Stays elevated longer than ASO.

The #1 Misuse

ASO should NOT be ordered to diagnose acute strep pharyngitis. The rapid strep test and throat culture are the tests for acute GAS. ASO is only useful when you suspect a post-streptococcal complication (ARF, PSGN, PANDAS) and need evidence of prior strep infection.

When to Order

• Suspected Acute Rheumatic Fever (ARF): Child with migratory polyarthritis, carditis (new murmur), chorea, erythema marginatum, or subcutaneous nodules 2–4 weeks after pharyngitis. ASO + anti-DNase B together provide the best sensitivity (~95% combined).
• Suspected Post-Streptococcal Glomerulonephritis (PSGN): Child with cola-colored urine, edema, hypertension 1–3 weeks after pharyngitis or 3–6 weeks after skin infection. Low C3 is the hallmark. ASO (pharyngeal) or anti-DNase B (skin) confirms recent strep.
• PANDAS/PANS evaluation: Controversial, but some clinicians check ASO/anti-DNase B in acute-onset OCD or tics following strep infection.

The Jones Criteria (2015 Updated)

ARF requires evidence of prior GAS infection (positive ASO/anti-DNase B, positive throat culture, or positive rapid strep) PLUS:

• Low-risk populations: 2 major criteria, OR 1 major + 2 minor criteria
• Moderate/high-risk populations: Same, but with expanded definitions (e.g., monoarthritis and lower fever thresholds qualify)

Major criteria: carditis, polyarthritis (or monoarthritis in high-risk), chorea, erythema marginatum, subcutaneous nodules. Minor criteria: fever, polyarthralgia (or monoarthralgia in high-risk), elevated ESR/CRP, prolonged PR interval.

Interpretation Pitfalls

• Elevated ASO alone doesn't mean anything pathologic: Up to 15–20% of school-age children have elevated ASO at any time from recent subclinical strep exposure. It must be interpreted in clinical context.
• A single ASO level is less useful than paired titers: A rising titer (4-fold increase between acute and convalescent specimens 2–4 weeks apart) is stronger evidence of recent infection than a single elevated level.
• ASO may be negative after skin infections: Streptolysin O is inactivated by skin lipids. For post-impetigo PSGN, anti-DNase B is more sensitive.
• Age-specific norms: Children normally have higher ASO levels than adults due to frequent strep exposure. Use age-appropriate reference ranges (>200 IU/mL is generally considered elevated in children; >160 in adults).
• Rheumatic heart disease without acute findings: In endemic areas, echocardiographic screening may detect subclinical rheumatic heart disease without a history of ARF. ASO may be normal by this point.

The PSGN Lab Pattern

This connects to the complement and urinalysis posts in this series:

• Low C3 (consumed via alternative pathway) with normal C4—the classic complement pattern for PSGN
• Urinalysis: Hematuria (dysmorphic RBCs, RBC casts), proteinuria
• Elevated ASO or anti-DNase B: Confirms recent strep
• C3 normalizes within 6–8 weeks. If C3 remains low beyond 8–12 weeks, suspect a different glomerulonephritis (lupus nephritis, MPGN, C3 glomerulopathy).

Bottom Line

ASO and anti-DNase B prove prior strep infection—they don't diagnose acute pharyngitis. Order them for suspected ARF or PSGN, not for sore throats. Use both together for best sensitivity. And remember: ASO is better for post-pharyngeal complications, anti-DNase B is better for post-skin-infection complications.

Stay sharp out there.

 

Lead Screening: The New Reference Value, Capillary vs. Venous, and the Management Tiers

There is no safe blood lead level. The threshold dropped to 3.5 µg/dL. And your patients in older housing are still at risk.

When to Screen

• Universal screening: Per AAP/CDC, screen all children at 12 months and 24 months (or 36–72 months if not previously tested).
• Targeted screening: Earlier or more frequent testing for children living in or visiting pre-1978 housing (especially pre-1950 with deteriorating paint), Medicaid-enrolled children (required at 12 and 24 months), children of immigrants/refugees, children with developmental delays or behavioral changes, siblings of lead-exposed children, children near industrial sources.
• Pregnant women: Screen at first prenatal visit if risk factors present (occupational exposure, pica, housing age, immigrant). Lead crosses the placenta.

The Reference Value: 3.5 µg/dL

In 2021, the CDC lowered the blood lead reference value (BLRV) from 5 to 3.5 µg/dL, based on the 97.5th percentile of the US pediatric population. This is NOT a "safe" threshold—there is no identified safe blood lead level. The BLRV is an action level: children at or above 3.5 require environmental investigation, nutritional counseling, and follow-up testing. It is updated every 4 years using NHANES data.

Capillary vs. Venous: The False-Positive Problem

Critical Pitfall

Capillary (fingerstick) lead levels have a high false-positive rate due to skin contamination. Any elevated capillary result must be confirmed with a venous draw before initiating management. Do not diagnose lead poisoning, report to the health department, or start chelation based on a capillary specimen alone. Venous blood lead level (BLL) is the definitive test.

Management Tiers

BLL (µg/dL)	Action
<3.5	Below reference value. Reassess at next well-child visit. Continue anticipatory guidance about lead hazards.
3.5–9	Confirm with venous draw if capillary. Provide nutritional counseling (iron, calcium, vitamin C promote iron absorption and reduce lead absorption). Environmental assessment and remediation. Retest in 1–3 months.
10–19	All of the above + environmental investigation by health department + closer follow-up (every 1–3 months). Consider iron studies (iron deficiency increases lead absorption). Neurodevelopmental screening.
20–44	All of the above + urgent environmental remediation + consider oral chelation (succimer) in consultation with toxicology/lead specialist. Abdominal X-ray if pica suspected (lead paint chips, foreign bodies).
45–69	Medical emergency. Chelation therapy required (oral succimer or IV CaNa2EDTA). Hospitalize if environment cannot be immediately made safe.
≥70	Medical emergency. Immediate hospitalization. IV chelation with dimercaprol (BAL) + CaNa2EDTA. Risk of encephalopathy, seizures, death.

The Iron Deficiency Connection

Iron deficiency and lead poisoning are synergistic. Iron-deficient children absorb more lead from the GI tract because lead and iron share the same intestinal transporter (DMT-1). Always check iron studies in a child with elevated lead, and treat iron deficiency aggressively. Adequate iron, calcium, and vitamin C intake is a key preventive strategy.

CBC Clues

Lead inhibits heme synthesis. Chronic lead exposure causes a microcytic, hypochromic anemia that mimics iron deficiency. The peripheral smear may show basophilic stippling (blue granules in RBCs from aggregated ribosomal RNA)—this is the classic smear finding of lead poisoning, connecting back to the CBC and peripheral smear posts in this series.

Bottom Line

Screen at 12 and 24 months. The reference value is 3.5. Always confirm capillary results with venous draws. Check iron studies in every lead-elevated child. And never forget that pre-1978 housing is the number-one risk factor in the US—especially relevant for your patients in older rural and urban housing stock here in Florida and across the Southeast.

Stay sharp out there.

Newborn Metabolic Screening: The Heel Stick That Saves Lives—and What to Do When It's Abnormal

 

Newborn Metabolic Screening: The Heel Stick That Saves Lives—and What to Do When It's Abnormal

RUSP conditions, premature infant false positives, the second screen, and the results that can't wait.

The newborn screening (NBS) panel is one of the most successful public health programs in history. A few drops of blood from a heel stick, collected 24–48 hours after birth, screen for dozens of conditions where early detection and treatment prevent death or irreversible disability. Yet many NPs don't know what's on the panel, what an abnormal result means, or how urgently to act.

What's Screened: The RUSP Core Conditions

The Recommended Uniform Screening Panel (RUSP) includes 37 core conditions and 26 secondary conditions. Every state screens for the core conditions, though the exact panel varies slightly by state. The critical time-sensitive conditions include:

Condition	Why It's Urgent	What Happens If Missed
Congenital hypothyroidism	Thyroid hormone essential for brain development	Irreversible intellectual disability ("cretinism") if untreated by 2–4 weeks
PKU (Phenylketonuria)	Cannot metabolize phenylalanine	Severe intellectual disability without dietary restriction
Galactosemia	Cannot metabolize galactose (in breast milk/formula)	E. coli sepsis, liver failure, death in first weeks
CAH (Congenital Adrenal Hyperplasia)	21-hydroxylase deficiency; salt-wasting crisis	Adrenal crisis, hyponatremia, hyperkalemia, shock, death by 2–3 weeks (salt-wasting form)
Sickle Cell Disease	Early penicillin prophylaxis prevents pneumococcal sepsis	Overwhelming sepsis and death in infancy without prophylaxis
CF (Cystic Fibrosis)	Early treatment improves pulmonary and nutritional outcomes	Failure to thrive, recurrent pneumonia, bronchiectasis
SCID (Severe Combined Immunodeficiency)	Added to RUSP in 2010 (TREC assay); pre-transplant management	Fatal infections by 1–2 years without bone marrow transplant
CCHD (Critical Congenital Heart Disease)	Pulse oximetry screening (not bloodwork); detect ductal-dependent lesions	Cardiovascular collapse when ductus closes

Additional core conditions include: medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, maple syrup urine disease, biotinidase deficiency, homocystinuria, congenital toxoplasmosis (some states), hearing loss (audiologic screen), and various organic acidemias and fatty acid oxidation disorders.

Timing and Collection

• First screen: 24–48 hours after birth (after adequate protein feeding to detect amino acid disorders). Screens collected before 24 hours have higher false-negative rates for some conditions.
• Second screen: Many states require a repeat at 1–2 weeks of age. This catches conditions that were falsely negative on the first screen (especially congenital hypothyroidism and CAH).
• Premature infants: The initial screen should still be collected, but a repeat is essential at 2 weeks or at discharge, whichever comes first. Premature infants have higher rates of false-positive AND false-negative results due to immature enzyme systems and transfusions.

When Time Is Critical

An abnormal NBS result for galactosemia, MSUD (maple syrup urine disease), or CAH salt-wasting form requires action within HOURS to DAYS. These are metabolic emergencies. When the state lab calls with a critical NBS result, treat it as urgently as a critical lab value in the ED. Refer immediately to the pediatric metabolic or endocrine specialist. Do not wait for confirmatory testing to initiate management for galactosemia (switch to soy formula immediately) or CAH (start hydrocortisone and fludrocortisone).

What to Do With an Abnormal Screen

1. Don't panic the family, but don't delay. An abnormal screen is not a diagnosis—it's a flag that requires confirmatory testing. But some conditions (above) can't wait.
2. Contact the state NBS follow-up program immediately for guidance on which specialist to involve and what confirmatory tests to order.
3. Confirmatory testing varies by condition: thyroid panel for congenital hypothyroidism, hemoglobin electrophoresis for sickle cell, sweat chloride test for CF, plasma amino acids for PKU/MSUD, 17-hydroxyprogesterone for CAH, TREC assay repeat + lymphocyte subsets for SCID.
4. Document and track. The most dangerous NBS failure is the abnormal result that gets lost in the system—the family was discharged, the result arrived at the hospital after discharge, and nobody followed up.

The #1 System Failure

The most common reason newborn screening fails to prevent disability is loss to follow-up—the result comes back abnormal but nobody contacts the family. If you see a newborn in primary care at the 2-week or 1-month visit, always verify that NBS results have been received and reviewed. If results aren't in the chart, track them down before the visit ends.

The Pitfalls

• False positives are common, especially in preterm infants. An abnormal screen is not a diagnosis. But it always requires follow-up.
• False negatives happen: congenital hypothyroidism can be missed on the first screen if the TSH hasn't risen yet (especially in central hypothyroidism, which NBS doesn't detect in most states). The second screen catches many of these.
• Transfused infants: Blood transfusions before NBS can cause false-negative results for hemoglobinopathies (the donor's normal hemoglobin masks the baby's abnormal hemoglobin). Repeat hemoglobin electrophoresis at 3–4 months in transfused infants.
• Carrier status detection: NBS may identify sickle cell trait (FAS pattern) or CF carrier status. These require genetic counseling but NOT treatment. Communicate clearly to families that carrier status is not disease.
• Home births and early discharges: Infants born at home or discharged before 24 hours are at higher risk for missed or improperly timed screens. Always verify screening status at the first primary care visit.

Bottom Line

Newborn screening is a time-sensitive public health program that prevents death and disability—but only if the results are received, reviewed, and acted on. Know which conditions require emergent action (galactosemia, CAH, MSUD). Know that an abnormal screen is a flag, not a diagnosis. Always verify NBS completion at the first primary care visit. And never let an abnormal result get lost in the system.

Stay sharp out there.

Cardiac Biomarkers: Troponin Trends, BNP Pitfalls, and the Chronic Elevation Problem

 

Cardiac Biomarkers: Troponin Trends, BNP Pitfalls, and the Chronic Elevation Problem

High-sensitivity troponin changed everything. BNP is falsely low in obesity. And a single troponin is almost never enough.

Troponin: The Myocardial Injury Marker

High-Sensitivity Troponin (hs-cTn)

High-sensitivity troponin assays detect far lower concentrations than older assays, enabling faster rule-out of MI but also detecting chronic low-level myocardial injury that was previously invisible. This has created a new problem: chronic troponin elevation without acute MI.

The Trend Is Everything

A single troponin value is not diagnostic. Acute MI shows a rise-and-fall pattern—troponin increases >20% from baseline over 3–6 hours. Chronic elevations (stable, flat values on serial testing) indicate non-ACS myocardial stress. Always order serial troponins at 0 and 3 hours (some protocols use 0 and 1 hour for rapid rule-out with hs-cTn). A flat troponin at two time points effectively rules out acute MI.

Non-ACS Causes of Elevated Troponin

• CKD/ESRD: Chronic low-level elevation from reduced clearance + subclinical ischemia. Present in up to 75% of dialysis patients.
• Heart failure: Myocardial wall stress causes chronic troponin leak.
• Pulmonary embolism: Right ventricular strain elevates troponin (prognostic, not diagnostic for PE).
• Sepsis: Demand ischemia and direct myocardial depression.
• Myocarditis: Often dramatic elevation without coronary obstruction.
• Tachyarrhythmias: Sustained rapid rates cause supply-demand mismatch.
• Takotsubo (stress) cardiomyopathy.
• Cardiac contusion, cardioversion, ablation.
• Extreme exercise: Marathon runners commonly have mildly elevated troponin post-race (resolves in 24–48 hours).

BNP and NT-proBNP: Heart Failure Markers

B-type natriuretic peptide (BNP) and its inactive fragment NT-proBNP are released by cardiomyocytes in response to volume overload and wall stress. They are used for diagnosis and monitoring of heart failure.

Marker	Heart Failure Unlikely	Gray Zone	Heart Failure Likely
BNP	<100 pg/mL	100–400	>400
NT-proBNP	<300 pg/mL	300–age-adjusted threshold	>450 (age <50), >900 (50–75), >1800 (age >75)

The Pitfalls

BNP Is Falsely LOW in Obesity

Adipose tissue expresses natriuretic peptide clearance receptors, causing BNP and NT-proBNP to be falsely low in obese patients. A BMI >35 patient with dyspnea and a BNP of 80 may actually have decompensated heart failure. Use lower thresholds in obese patients (some guidelines suggest halving the cutoff).

• NT-proBNP is renally cleared: Levels are elevated in CKD/ESRD independent of volume status. BNP is less affected by renal function.
• NT-proBNP increases with age: Use age-adjusted thresholds (see table above).
• Atrial fibrillation elevates both BNP and NT-proBNP independent of heart failure.
• Sacubitril/valsartan (Entresto) inhibits BNP degradation, falsely elevating BNP. Monitor with NT-proBNP instead in patients on this medication.
• Both markers are elevated in PE (right heart strain), sepsis, and severe pneumonia—don't assume heart failure without echocardiographic correlation.

Bottom Line

Troponin is a myocardial injury marker, not an MI-specific marker. The trend (rise-and-fall vs. flat) distinguishes acute MI from chronic elevation. BNP/NT-proBNP diagnose and monitor heart failure but are falsely low in obesity and falsely high in CKD, AF, and PE. Always correlate with the clinical picture and use serial measurements.

Stay sharp out there.

Viral Serologies: IgG vs. IgM for EBV, CMV, Parvovirus, and When to Suspect Each Infection

 

Viral Serologies: IgG vs. IgM for EBV, CMV, Parvovirus, and When to Suspect Each Infection

IgM means acute. IgG means past. Except when it doesn't. Here's how to interpret the viral serology panel without getting fooled.

The Universal Principle: IgM vs. IgG

• IgM: The first antibody produced during acute infection. Appears within days to 1–2 weeks of infection. Generally indicates acute or recent infection. Declines over weeks to months.
• IgG: Appears later (2–4 weeks), rises during convalescence, and persists for years to lifetime. Indicates past exposure/immunity.
• IgM positive + IgG negative = early acute infection (seroconversion in progress)
• IgM positive + IgG positive = recent or acute infection (IgG just appearing)
• IgM negative + IgG positive = past infection/immunity
• Both negative = no exposure (susceptible)

The IgM Caveat

IgM is NOT always reliable for timing. False-positive IgM can occur with: polyclonal immune activation (autoimmune diseases, other concurrent infections), rheumatoid factor interference (RF is an IgM that can cross-react in serologic assays), and persistent IgM (some infections like EBV can have detectable IgM for months). Always interpret IgM in clinical context, not as a standalone timestamp.

Virus-by-Virus Guide

EBV (Epstein-Barr Virus) — Infectious Mononucleosis

When to suspect: Adolescents/young adults with fever, severe pharyngitis, posterior cervical lymphadenopathy, fatigue, splenomegaly. Also consider in any age with prolonged febrile illness, atypical lymphocytes on CBC, or hepatitis.

Test	What It Means
VCA IgM (Viral Capsid Antigen)	Positive in acute infection. Appears early, disappears in 4–8 weeks. The best marker for acute mono.
VCA IgG	Appears during acute infection and persists for life. Positive alone = past infection.
EA IgG (Early Antigen)	Appears in acute infection, disappears in 3–6 months. Supports recent infection but present in only ~70% of acute cases.
EBNA IgG (EBV Nuclear Antigen)	Appears 6–12 weeks after onset. Negative in acute mono, positive in past infection. The key test that distinguishes acute from past.
Heterophile antibody (Monospot)	Rapid test. ~85% sensitive in adults/adolescents. Can be negative in children <4 years (up to 50% false-negative rate). If monospot is negative but EBV is suspected, order the full EBV panel.

The Acute EBV Pattern

VCA IgM positive + VCA IgG positive + EA IgG positive + EBNA IgG negative = acute infectious mononucleosis. Once EBNA becomes positive, the infection is past the acute phase. VCA IgG positive + EBNA positive + everything else negative = remote past infection.

Pediatric Pearl

In children <4 years, EBV often presents atypically (rash, irritability, mild URI symptoms) and the monospot has a high false-negative rate. Use the EBV-specific antibody panel instead. Also: EBV + amoxicillin = the classic maculopapular rash (occurs in ~70–100% of mono patients given amoxicillin—not a true drug allergy, but an immune-mediated reaction specific to the EBV context).

CMV (Cytomegalovirus)

When to suspect: Mono-like illness with negative monospot/EBV panel ("heterophile-negative mono"). Immunocompromised patients (transplant, HIV) with end-organ disease. Pregnancy screening when primary CMV is suspected (congenital CMV risk).

• CMV IgM positive: Acute or recent infection (but can persist for months and has false positives from RF).
• CMV IgG positive, IgM negative: Past infection. In immunocompetent patients, this is the most common finding and requires no action.
• CMV IgG avidity: High avidity = infection >3–4 months ago. Low avidity = recent infection (<3–4 months). Essential in pregnancy to time the infection relative to conception.
• CMV PCR (DNA viral load): The test for active CMV disease in immunocompromised patients. Serology is less useful in this population—they may not mount an adequate antibody response.

Pregnancy Pitfall

Primary CMV infection during pregnancy (especially first trimester) carries the highest risk of congenital CMV (hearing loss, microcephaly, intellectual disability). If a pregnant patient has CMV IgM positive, CMV IgG avidity is essential to determine if the infection is recent (low avidity = high risk to fetus) or past (high avidity = lower risk). Do not diagnose primary CMV in pregnancy on IgM alone—IgM can persist and give false-positive "acute" results months after the actual infection.

Parvovirus B19

When to suspect: "Slapped cheek" rash (erythema infectiosum/fifth disease) in children. In adults: symmetric polyarthralgia (especially hands/wrists, mimicking RA), reticulocytopenic anemia (aplastic crisis in sickle cell patients), hydrops fetalis in pregnancy.

• Parvovirus IgM: Appears by day 10–12 of infection, persists for 2–3 months. Indicates acute/recent infection.
• Parvovirus IgG: Appears by week 3, persists for life. Indicates immunity.
• Parvovirus PCR: Detects viral DNA. Essential in immunocompromised patients (who may not produce IgM) and for diagnosing chronic parvovirus infection (persistent anemia in immunosuppressed patients).

Clinical Pearls

• Parvovirus arthritis mimics early RA: Symmetric small joint polyarthralgia in a young woman with recent viral symptoms and a positive parvovirus IgM. Don't start methotrexate—it's self-limited (weeks to months).
• Aplastic crisis in sickle cell: Parvovirus infects erythroid precursors. In patients with chronic hemolysis (sickle cell, spherocytosis), this causes an abrupt reticulocytopenic anemia. Check parvovirus IgM in any sickle cell patient with sudden worsening anemia.
• Pregnancy: Primary parvovirus in the first/second trimester can cause fetal hydrops and death. If exposure is suspected, check IgM and IgG immediately. IgG positive/IgM negative = immune, no risk. IgM positive = refer to MFM urgently for fetal monitoring.

Other Viral Serologies to Know

Virus	When to Suspect	Key Tests	Pitfall
Hepatitis A	Acute hepatitis, travel exposure, foodborne outbreak	HAV IgM (acute), HAV total Ab/IgG (immunity)	Total anti-HAV is positive from past infection OR vaccination—can't distinguish without IgM
Measles	Fever, cough, coryza, conjunctivitis, maculopapular rash, Koplik's spots; unvaccinated or under-vaccinated	Measles IgM (acute, draw at rash onset), measles IgG (immunity check)	IgM may be negative in first 72 hours of rash; repeat if initially negative. Measles IgG confirms vaccination immunity.
Varicella (VZV)	Chickenpox (vesicular rash); immunity check pre-transplant or in healthcare workers	VZV IgG (immunity), VZV IgM (acute—rarely needed, as diagnosis is usually clinical)	VZV IgG confirms immunity from prior infection or vaccination. IgG-negative patients need vaccination (live vaccine—contraindicated in immunosuppressed).
HSV (covered in STI post)	Genital/oral lesions	PCR swab of lesion (gold standard); type-specific IgG for remote diagnosis	Don't screen asymptomatic patients. Low-index-value HSV-2 IgG has high false-positive rate.
HIV (covered in STI post)	Risk factors, acute retroviral syndrome	4th-gen Ag/Ab combo (screen); differentiation assay + RNA (confirm)	Window period 2–4 weeks with 4th-gen. Use RNA for very early suspected infection.
Mumps	Parotitis, orchitis; outbreaks in vaccinated populations	Mumps IgM (acute), PCR (buccal swab preferred)	IgM may be absent in vaccinated individuals with breakthrough mumps; PCR is more reliable.
Rubella	Pregnancy immunity screen; rash illness with arthralgia	Rubella IgG (immunity), IgM (acute); IgG avidity in pregnancy	IgM can persist for months; avidity testing helps time the infection in pregnancy.

When to Use Serology vs. PCR

• Serology (IgG/IgM): Best for immunocompetent patients with intact antibody responses. Tells you about exposure and timing.
• PCR (viral DNA/RNA): Best for immunocompromised patients (may not produce adequate antibodies), for detecting active viral replication, and for confirming acute infection when serology is ambiguous. Essential for CMV and EBV in transplant patients, parvovirus in immunosuppressed, and HSV in active lesions.

The Pitfalls Summary

• IgM can persist for months (especially EBV, CMV)—a positive IgM alone doesn't prove the infection is happening right now.
• Rheumatoid factor causes false-positive IgM in multiple viral assays—if the patient has RA or other conditions with elevated RF, interpret IgM cautiously.
• Monospot is unreliable in young children—use the full EBV panel for kids <4.
• Serology is unreliable in immunocompromised patients—use PCR for CMV, EBV, and parvovirus in transplant recipients and HIV patients.
• Avidity testing is essential in pregnancy for CMV and rubella when IgM is positive—it's the test that determines fetal risk.
• Parvovirus arthritis mimics RA—check parvovirus IgM before starting DMARDs in a patient with acute-onset symmetric polyarthritis.

Bottom Line

Viral serologies follow a consistent IgM (acute) and IgG (past) framework, but the devil is in the details: persistent IgM, RF interference, monospot limitations in children, and the critical role of avidity testing in pregnancy. Know each virus's unique antibody pattern (especially EBV's four-marker panel), use PCR when serology is unreliable, and never start immunosuppressive therapy for "RA" without ruling out parvovirus first.

Stay sharp out there.